Please enable JavaScript to continue using this application.

Compare $CYTK vs $PTGX | Chartloom

Compare

$CYTK vs $PTGX

Cytokinetics Inc · Protagonist Therapeutics Inc

CYTK

Cytokinetics Inc

PTGX

Protagonist Therapeutics Inc

Compare $CYTK vs $PTGX

Comparing Cytokinetics Inc and Protagonist Therapeutics Inc

CYTKCytokinetics Inc

PTGXProtagonist Therapeutics Inc

CYTKCytokinetics Inc

Market cap

$8.53B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

33.61x

Rev growth (TTM)

-21.1%

YTD performance

1.9%

52W performance

3.4%

FCF yield

-6.8%

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CYTK

PTGX

Detailed metrics comparison

CYTK

Cytokinetics Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

CYTK$8.53B

PTGX$9.24B

Enterprise Value

CYTK$9.42B

PTGX$8.82B

Price

CYTK$62.91

PTGX$143.73

P/E Ratio

CYTKN/A

PTGX123.10x

P/S Ratio

CYTK126.04x

PTGX32.78x

EV/Sales

CYTK139.22x

PTGX31.29x

EV/EBITDA

CYTK1,193.30x

PTGX140.17x

P/B Ratio

CYTK83.67x

PTGX10.77x

P/FCF Ratio

CYTKN/A

PTGX70.79x

EV/FCF

CYTK-16.22x

PTGX67.57x

PEG Ratio

CYTKN/A

PTGX2.95x

Forward P/E (NTM)

CYTKN/A

PTGX77.71x

Forward P/S (NTM)

CYTK33.61x

PTGX23.74x

Revenue (TTM)

CYTK$68M

PTGX$282M

Revenue Growth (YoY)

CYTK-21.1%

PTGX34.8%

Forward Rev Growth

CYTK183.7%

PTGX-70.6%

Gross Margin (TTM)

CYTK58.9%

PTGX0.0%

Operating Margin (TTM)

CYTK0.0%

PTGX20.7%

EBITDA Margin (TTM)

CYTK-1027.6%

PTGX21.2%

Net Margin (TTM)

CYTK-1321.1%

PTGX29.4%

FCF Margin (TTM)

CYTK-858.2%

PTGX46.3%

Net Income (TTM)

CYTK$-894M

PTGX$83M

FCF (TTM)

CYTK$-581M

PTGX$131M

EPS (TTM)

CYTK-$6.77

PTGX$1.17

ROE (TTM)

CYTK-13119.0%

PTGX12.0%

ROA (TTM)

CYTK-5902.0%

PTGX11.2%

ROIC (TTM)

CYTK-1872.0%

PTGX12.0%

Cash

CYTK$255M

PTGX$420M

Debt

CYTK$1.15B

PTGX$0

Net Cash/Debt

CYTK$-892M

PTGX$420M

Current Ratio (TTM)

CYTK6.66x

PTGX21.71x

Quick Ratio (TTM)

CYTK6.56x

PTGX21.58x

Debt/Equity (TTM)

CYTK6.01x

PTGX0.00x

Debt/Assets (TTM)

CYTK0.0%

PTGX0.0%

Interest Coverage (TTM)

CYTKN/A

PTGXN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

PTGX0.00x

Beta

CYTK0.42

PTGX1.19

52W Performance

CYTK3.4%

PTGX120.1%

YTD Performance

CYTK1.9%

PTGX64.9%

% from 52W High

CYTK-28.8%

PTGX-10.6%

% from 52W Low

CYTK15.9%

PTGX119.2%

Asset Turnover (TTM)

CYTK0.04x

PTGX0.38x

FCF Yield (TTM)

CYTK-6.8%

PTGX1.4%

Earnings Yield (TTM)

CYTK-10.5%

PTGX0.9%

Dividend Yield (TTM)

CYTKN/A

PTGXN/A

Rule of 40

CYTK-879.2

PTGX81.1

EV/GP/RG

CYTK0.73

PTGXN/A

Ticker research

View CYTK research View PTGX research

Metric	CYTK Cytokinetics Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$9.24B
Enterprise Value	$9.42B	$8.82B
Price	$62.91	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	126.04x	32.78x
EV/Sales	139.22x	31.29x
EV/EBITDA	1,193.30x	140.17x
P/B Ratio	83.67x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-16.22x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	33.61x	23.74x
Revenue & Growth
Revenue (TTM)	$68M	$282M
Revenue Growth (YoY)	-21.1%	34.8%
Forward Rev Growth	183.7%	-70.6%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-1027.6%	21.2%
Net Margin (TTM)	-1321.1%	29.4%
FCF Margin (TTM)	-858.2%	46.3%
Net Income (TTM)	$-894M	$83M
FCF (TTM)	$-581M	$131M
EPS (TTM)	-$6.77	$1.17
ROE (TTM)	-13119.0%	12.0%
ROA (TTM)	-5902.0%	11.2%
ROIC (TTM)	-1872.0%	12.0%
Financial Health
Cash	$255M	$420M
Debt	$1.15B	$0
Net Cash/Debt	$-892M	$420M
Current Ratio (TTM)	6.66x	21.71x
Quick Ratio (TTM)	6.56x	21.58x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	1.19
52W Performance	3.4%	120.1%
YTD Performance	1.9%	64.9%
% from 52W High	-28.8%	-10.6%
% from 52W Low	15.9%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.38x
FCF Yield (TTM)	-6.8%	1.4%
Earnings Yield (TTM)	-10.5%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	81.1
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View PTGX research

Valuation

P/E Ratio

PTGX

123.10x

P/S Ratio

PTGX

32.78x

CYTK

126.04x

EV/FCF

CYTK

-16.22x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

PTGX

34.8%

CYTK

-21.1%

Forward Revenue Growth

CYTK

183.7%

PTGX

-70.6%

Profitability & performance

Gross Margin

CYTK

58.9%

PTGX

0.0%

ROE

PTGX

12.0%

CYTK

-13119.0%

FCF Yield %

PTGX

1.4%

CYTK

-6.8%

52-Week Performance

PTGX

120.1%

CYTK

3.4%

Detailed metrics comparison

CYTK

Cytokinetics Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

CYTK$8.53B

PTGX$9.24B

Enterprise Value

CYTK$9.42B

PTGX$8.82B

Price

CYTK$62.91

PTGX$143.73

P/E Ratio

CYTKN/A

PTGX123.10x

P/S Ratio

CYTK126.04x

PTGX32.78x

EV/Sales

CYTK139.22x

PTGX31.29x

EV/EBITDA

CYTK1,193.30x

PTGX140.17x

P/B Ratio

CYTK83.67x

PTGX10.77x

P/FCF Ratio

CYTKN/A

PTGX70.79x

EV/FCF

CYTK-16.22x

PTGX67.57x

PEG Ratio

CYTKN/A

PTGX2.95x

Forward P/E (NTM)

CYTKN/A

PTGX77.71x

Forward P/S (NTM)

CYTK33.61x

PTGX23.74x

Revenue (TTM)

CYTK$68M

PTGX$282M

Revenue Growth (YoY)

CYTK-21.1%

PTGX34.8%

Forward Rev Growth

CYTK183.7%

PTGX-70.6%

Gross Margin (TTM)

CYTK58.9%

PTGX0.0%

Operating Margin (TTM)

CYTK0.0%

PTGX20.7%

EBITDA Margin (TTM)

CYTK-1027.6%

PTGX21.2%

Net Margin (TTM)

CYTK-1321.1%

PTGX29.4%

FCF Margin (TTM)

CYTK-858.2%

PTGX46.3%

Net Income (TTM)

CYTK$-894M

PTGX$83M

FCF (TTM)

CYTK$-581M

PTGX$131M

EPS (TTM)

CYTK-$6.77

PTGX$1.17

ROE (TTM)

CYTK-13119.0%

PTGX12.0%

ROA (TTM)

CYTK-5902.0%

PTGX11.2%

ROIC (TTM)

CYTK-1872.0%

PTGX12.0%

Cash

CYTK$255M

PTGX$420M

Debt

CYTK$1.15B

PTGX$0

Net Cash/Debt

CYTK$-892M

PTGX$420M

Current Ratio (TTM)

CYTK6.66x

PTGX21.71x

Quick Ratio (TTM)

CYTK6.56x

PTGX21.58x

Debt/Equity (TTM)

CYTK6.01x

PTGX0.00x

Debt/Assets (TTM)

CYTK0.0%

PTGX0.0%

Interest Coverage (TTM)

CYTKN/A

PTGXN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

PTGX0.00x

Beta

CYTK0.42

PTGX1.19

52W Performance

CYTK3.4%

PTGX120.1%

YTD Performance

CYTK1.9%

PTGX64.9%

% from 52W High

CYTK-28.8%

PTGX-10.6%

% from 52W Low

CYTK15.9%

PTGX119.2%

Asset Turnover (TTM)

CYTK0.04x

PTGX0.38x

FCF Yield (TTM)

CYTK-6.8%

PTGX1.4%

Earnings Yield (TTM)

CYTK-10.5%

PTGX0.9%

Dividend Yield (TTM)

CYTKN/A

PTGXN/A

Rule of 40

CYTK-879.2

PTGX81.1

EV/GP/RG

CYTK0.73

PTGXN/A

Ticker research

View CYTK research View PTGX research

Metric	CYTK Cytokinetics Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$9.24B
Enterprise Value	$9.42B	$8.82B
Price	$62.91	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	126.04x	32.78x
EV/Sales	139.22x	31.29x
EV/EBITDA	1,193.30x	140.17x
P/B Ratio	83.67x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-16.22x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	33.61x	23.74x
Revenue & Growth
Revenue (TTM)	$68M	$282M
Revenue Growth (YoY)	-21.1%	34.8%
Forward Rev Growth	183.7%	-70.6%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-1027.6%	21.2%
Net Margin (TTM)	-1321.1%	29.4%
FCF Margin (TTM)	-858.2%	46.3%
Net Income (TTM)	$-894M	$83M
FCF (TTM)	$-581M	$131M
EPS (TTM)	-$6.77	$1.17
ROE (TTM)	-13119.0%	12.0%
ROA (TTM)	-5902.0%	11.2%
ROIC (TTM)	-1872.0%	12.0%
Financial Health
Cash	$255M	$420M
Debt	$1.15B	$0
Net Cash/Debt	$-892M	$420M
Current Ratio (TTM)	6.66x	21.71x
Quick Ratio (TTM)	6.56x	21.58x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	1.19
52W Performance	3.4%	120.1%
YTD Performance	1.9%	64.9%
% from 52W High	-28.8%	-10.6%
% from 52W Low	15.9%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.38x
FCF Yield (TTM)	-6.8%	1.4%
Earnings Yield (TTM)	-10.5%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	81.1
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View PTGX research